These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1046 related items for PubMed ID: 24582013

  • 1. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Koerdt S, Otto S, Pautke C.
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [Abstract] [Full Text] [Related]

  • 2. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
    Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Otto S, Pautke C.
    J Oral Maxillofac Surg; 2014 May; 72(5):903-10. PubMed ID: 24485975
    [Abstract] [Full Text] [Related]

  • 3. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
    Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Ristow M, Koerdt S, Schuster R, Otto S, Pautke C.
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):487-93. PubMed ID: 24469255
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B, Drudge-Coates L, Ali S, Pati J, Nargund V, Ali E, Cheng L, Wells P.
    Urol Nurs; 2016 Mar; 36(3):111-6, 154. PubMed ID: 27501591
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Review of current literature and implications of RANKL inhibitors for oral health care providers.
    Epstein MS, Ephros HD, Epstein JB.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
    [Abstract] [Full Text] [Related]

  • 9. The effects of bisphosphonate on the remodeling of different irregular bones in mice.
    Su J, Feng M, Han W, Zhao H.
    J Oral Pathol Med; 2015 Sep; 44(8):638-48. PubMed ID: 25370709
    [Abstract] [Full Text] [Related]

  • 10. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
    de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, Boyce RW, Dwyer D, Aghaloo TL, Tetradis S.
    J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
    [Abstract] [Full Text] [Related]

  • 11. Infection and medication-related osteonecrosis of the jaw.
    Katsarelis H, Shah NP, Dhariwal DK, Pazianas M.
    J Dent Res; 2015 Apr; 94(4):534-9. PubMed ID: 25710950
    [Abstract] [Full Text] [Related]

  • 12. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B.
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis.
    Aoki K, Matsunaga S, Ito S, Shibahara T, Nomura T, Matsuzaki H, Abe S, Yamaguchi A.
    J Bone Miner Metab; 2021 Sep; 39(5):737-747. PubMed ID: 33830351
    [Abstract] [Full Text] [Related]

  • 15. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
    Rachner TD, Platzbecker U, Felsenberg D, Hofbauer LC.
    Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intraindividual comparison of preoperative (99m)Tc-MDP SPECT/CT and intraoperative and histopathological findings in patients with bisphosphonate- or denosumab-related osteonecrosis of the jaw.
    Assaf AT, Zrnc TA, Remus CC, Adam G, Zustin J, Heiland M, Friedrich RE, Derlin T.
    J Craniomaxillofac Surg; 2015 Oct; 43(8):1461-9. PubMed ID: 26232916
    [Abstract] [Full Text] [Related]

  • 18. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC.
    J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
    [Abstract] [Full Text] [Related]

  • 19. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
    Sivolella S, Lumachi F, Stellini E, Favero L.
    Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
    [Abstract] [Full Text] [Related]

  • 20. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
    You Tm, Lee KH, Lee SH, Park W.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.